LungLife AI (LSE:LLAI) Gross-Profit-to-Asset % : 0.42% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is LungLife AI Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. LungLife AI's annualized Gross Profit for the quarter that ended in Dec. 2023 was £0.04 Mil. LungLife AI's average Total Assets over the quarter that ended in Dec. 2023 was £8.56 Mil. Therefore, LungLife AI's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 0.42%.

LungLife AI Gross-Profit-to-Asset % Historical Data

The historical data trend for LungLife AI's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LungLife AI Gross-Profit-to-Asset % Chart

LungLife AI Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

-1.06

1.37

0.87

0.14

0.36

LungLife AI Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial					1.49	0.10	0.16	0.33	0.42

Competitive Comparison of LungLife AI's Gross-Profit-to-Asset %

For the Diagnostics & Research subindustry, LungLife AI's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LungLife AI's Gross-Profit-to-Asset % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, LungLife AI's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where LungLife AI's Gross-Profit-to-Asset % falls into.

LungLife AI Gross-Profit-to-Asset % Calculation

LungLife AI's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	0.036	/	( (12.331	+	7.522)	/ 2 )
	=	0.036	/	9.9265
	=	0.36 %

LungLife AI's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	0.036	/	( (9.6	+	7.522)	/ 2 )
	=	0.036	/	8.561
	=	0.42 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

LungLife AI Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of LungLife AI's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

LungLife AI (LSE:LLAI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » LungLife AI Inc (LSE:LLAI) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

N/A

Address

2545 W. Hillcrest Drive, Suite 140, Thousand Oaks, CA, USA, 91320

Website

https://www.lunglifeai.com

LungLife AI Inc is a diagnostic company focused on the early detection of lung cancer from a simple blood draw enhanced by artificial intelligence. Its LungLB Test is a blood-based tool developed to provide clinicians the information needed to make informed decisions about the management of lung nodules and lung cancer.

LungLife AI (LSE:LLAI) Headlines

No Headlines